Rättelse: Kallelse till extra bolagsstämma IDL Biotech

IDL Biotech håller extra bolagsstämma 20 augusti 2021

Delårsrapport Q2 2021

IDL Biotech AB avnoteras från Spotlight Stock Market

Spotlight har efter ansökan från IDL Biotech AB (Bolaget) beslutat att avnotera Bolagets aktie (IDL). Sista dag för handel i Bolagets aktier är den 4 augusti 2021.

IDL har ansökt om avnotering från Spotlight Stock Market

Den 10 maj 2021 offentliggjorde AroCell AB (publ) ("AroCell") ett offentligt erbjudande till aktieägarna i IDL Biotech AB ("IDL"), att överlåta samtliga utestående aktier i IDL till AroCell. Erbjudandet har accepterats av aktieägare representerandes totalt 60 487 373 aktier i IDL, vilket motsvarar 95,92 procent av aktierna och rösterna i IDL. Mot bakgrund av ovanstående anser styrelsen för IDL att det inte längre är motiverat för IDL att verka i en noterad miljö och bolaget har därför den 20 juli beslutat om att ansöka om avnotering från Spotlight Stock Market.

Arocell AB förklarar erbjudandet till aktieägarna i IDL Biotech AB ovillkorat och fullföljer erbjudandet

Den 10 maj 2021 offentliggjorde AroCell AB (publ) ("AroCell") ett offentligt uppköpserbjudande till aktieägarna i IDL Biotech AB ("IDL") ("Erbjudandet"). Den 1 juli 2021 offentliggjorde AroCell beslutet att fullfölja Erbjudandet samt att förlänga acceptfristen för Erbjudandet till och med den 9 augusti 2021 för att kvarvarande aktieägare ska ges möjlighet att acceptera Erbjudandet

Kompletterande information till Årsstämman 23 juni.

Aktieägarna i IDL Biotech AB (publ), org nr 556339-4203, (”bolaget”), kallas såsom tidigare meddelats till årsstämma den 23 juni. Stämman kommer att hållas som en poströstningsstämma. Härmed lämnas följande kompletterande information avseende punkterna 10 och 11 i Förslag till dagordning.

Uttalande från den Oberoende Budkommittén för IDL Biotech AB med anledning av AroCell AB:s (publ) offentliga uppköpserbjudande

Den Oberoende Budkommittén för IDL Biotech AB (”IDL” eller ”Bolaget”) rekommenderar aktieägarna att acceptera det offentliga uppköpserbjudandet om 0,63 aktier i AroCell AB (publ) (”AroCell” eller ”Budgivaren”) per aktie i IDL som lämnats av Budgivaren den 10 maj 2021.

Kallelse till årsstämma i IDL Biotech (publ)

Aktieägarna i IDL Biotech kallas härmed till årsstämma den 23 juni. Stämman kommer att hållas som en poströstningsstämma.

AroCell AB (publ) riktar offentligt uppköpserbjudande till aktieägarna i IDL Biotech AB (publ)

IDL Biotech AB uppmärksammar härmed att AroCell AB (publ) idag har lämnat ett uppköpserbjudande till aktieägarna i IDL att överlåta samtliga aktier till AroCell i utbyte mot 0,63 AroCell-aktier för varje aktie i IDL.

IDL Biotech is making progress in Africa

IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company delivers TUBEX® TF.

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

IDL Biotech continues its work on automating the TPS® tumor marker

As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the first phase has been completed. Thus, the last phase before launch now begins. The hope is that the product will be available on the Chinese market by the end of 2021.

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

“IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.

IDL Biotech develops rapid test for breast cancer

In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer.

Ledamöterna i valberedningen för IDL Biotech är utsedda

I enlighet med beslut vid årsstämman som hölls den 27 maj 2020 har styrelsens ordförande i IDL Biotech tillsett att bolagets röstmässigt tre största aktieägare har erbjudits att vardera utse varsin representant att ingå i valberedningen.

IDL Biotech AB has appointed a new CEO

Gunnar Wahlberg was appointed as the new CEO of IDL Biotech from the 1st of December 2020. Gunnar has served as acting CEO since the 1st of September after the previous CEO left the post on the 31st of August. Gunnar Wahlberg has previously been a part of IDL Biotech group executive board and worked as Head of Sales since spring of 2019.

IDL Biotech is planning for clinical studies in the United States of America for its rapid diagnostic test for bladder cancer, UBC® Rapid.

In 2019, IDL Biotech submitted a so-called “Pre-submission request” to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the company’s rapid diagnostic test for bladder cancer. As of now, the company is proceeding with preparations of clinical trial in the United States of America.

Gunnar Wahlberg appointed as acting CEO

The Board has appointed Gunnar Wahlberg as acting CEO.

IDL has hired a new production manager

IDL is proud to announce that Jeanpierre Salas Montes will take over as production manager at IDL Biotech. Ola Eklund has decided to retire after more than 20 years at IDL.

Charlotte Berg leaves the position as CEO of IDL Biotech AB (publ)

IDL Biotech's CEO, Charlotte Berg, has informed the Board that, after more than ten years at the company, she wishes to resign as CEO to start another assignment in a non-competing company.

Business Development Manager Asia

IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF.

Two new publications on UBC Rapid

A publication presented in Entropy shows the value of UBC® Rapid

Annual meeting/Årsstämma

Årsstämma hålls den 27 maj 2020 kl. 15.00 på Piperska Muren, Scheelegatan 14, 112 28 Stockholm.

IDL Biotech signs new distribution agreement with Beckman Coulter, which gives the distributor global sales rights for the company's tumor markers on the ELISA manual platform.

Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers, we can intensify our focus on rapid testing and automation. At the same time, it gives Beckman Coulter the opportunity to broaden his product portfolio within tumor markers, ”says Charlotte Berg, CEO of IDL Biotech. IDL Biotech will continue to produce the tumor markers. The agreement is global, excluding the Chinese market.

IDL Biotech signs distributor agreement in Zimbabwe

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with PHM Diagnostic Lab Ltd in Zimbabwe.

Registration of TUBEX TF approved in Indonesia

The registration of TUBEX TF has been approved in Indonesia.

Distribution agreement signed in Malaysia

IDL has signed a distribution agreement in Malaysia

Meta analysis on TUBEX

Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance.

IDL signs distribution agreement in Uganda

IDL has signed a new distribution agreement in Uganda

IDL signed two new distributions agreements

IDL has signed two new distributions agreements.

IDL Biotech knyter till sig världskänd Vetenskaplig Rådgivare

IDL Biotech fortsätter förstärka sitt globala team. Sam Kariuki, med över trettio års erfarenhet inom tropisk medicin, är ny Vetenskaplig Rådgivare till bolaget.

IDL Biotech AB har haft uppföljningsmöte med FDA

I juli lämnade IDL Biotech in underlag, så kallad Pre-submission request, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande för försäljning i USA av UBC® Rapid, bolagets snabbtest för blåscancer. Idag genomfördes det första uppföljningsmötet med FDA.

IDL Biotech licensierar sin produktlinje för tumörmarkörer på den manuella plattformen radioimmunoassay till Beckman Coulter Diagnostics

IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL att erhålla royalties. Avtalet har formellt undertecknats av Immunotech, ett dotterbolag till Beckman Coulter.

Meet us

IDL will participate at Svenska Urologidagarna 2-4 October 2019 at Aros Congress Center. IDL will also be presented at Medica i Düsseldorf, 18-21 November 2019 in Hall 1 at location D34 . We are looking forward to meeting you there.!

IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.

IDL Biotech has started the work on mapping the US market.

IDL Biotech launches TUBEX TF in Kenya

On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya.

Jerker Swanstein new Chairman of the Board of Directors

The annual general meeting, held 28th of May 2019, re-elected Jerker Swanstein, Per-Anders Abrahamsson and Carsten Olsson, and elected Malin Ruijsenaars and Eva Sjökvist Saers as new members of the Board of Directors. During the statutory meeting held 28th of May 2019 Jerker Swanstein was selected as new Chairman of the Board of Directors.

Information from the Annual General Meeting

The Annual General meeting was held on the 28th of May 2019.

Notice of Annual General Meeting 2019

The shareholders of IDL Biotech AB (publ) are hereby invited to the Annual General Meeting on Tuesday, 28 May 2019, 15.00 at Redeye AB, Mäster Samuelsgatan 42, 10387 Stockholm.

IDL in the Spotlight

Spotlight has produced a short film about IDL Biotech.

Meet IDL Biotech at Coalition against Typhoid Fever

Every two years, the Coalition against Typhoid, based at the Sabin Vaccine Institute (Sabin), convenes the International Conference on Typhoid and Other Invasive Salmonelloses. The 11th International Conference on Typhoid and Other Invasive Salmonelloses will be held from March 26-28, 2019 in Hanoi, Vietnam. IDL Biotech is proud to be a sponsor of this important conference.

SvD Börspluspod

CEO Charlotte Berg is interviewed in the latest podcast from SvD Börspluspod.

Interview with CEO Charlotte Berg

Börshajen has published an interview with Charlotte Berg, CEO at IDL Biotech.

Nomination Committe for IDL appointed

IDL Biotechs extra ordinary general meeting held on the 25th October 2018 decided to establish a nomination committee.

German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer

International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy.

Interview with Charlotte Berg

On Saturday the 17th of November, the Swedish newspaper SvD, had an interview with the CEO, Charlotte Berg.

IDL Biotech AB offentliggör prospekt för beslutad företrädesemission

Styrelsen i IDL Biotech AB (Publ) har upprättat ett prospekt med anledning av den förestående nyemissionen med företrädesrätt för IDL Biotechs aktieägare. Prospektet har idag godkänts och registrerats av Finansinspektionen.

Information from Extraordinary General Meeting

The Extraordinary meeting was held on 2018-10-26.

Redeye Life Science Day

IDL Biotech will attend Redeye Life Science Day on November 21, at Haymarket City Scandic Stockholm, Hötorget 13-15, Stockholm. Charlotte Berg, CEO, will have her presentation at 1 pm. The presentation is live on www.redeye.se/live/lsday-2018. You can follow the presentation through the computer or cellphone.

IDL strengthens the team with Regional Manager Asia Pacific

IDL has appointed Nick Thilveris as our new Regional Manager Asia Pacific

Notice of Extra Annual General Meeting

The Extra Annual General Meeting will be held 25th of October.

New Share Issue

The board of directors of IDL Biotech AB (publ) has resolved to make a new share issue of approximately SEK 39,4 million before issue costs.

IDL to strengthen global sales

IDL Biotech today announced that they are strengthening their global Sales and Marketing team. Martyn Eales has been named Senior Vice President of Global Sales and Marie Torstensson has been named Marketing Manager. Together they will lead the effort to increase international sales.

Patent approved in Europe

During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.

Per-Anders Abrahamsson New Scientific Advisor to IDL Biotech AB

Per-Anders Abrahamsson, MD, PhD, Professor in Urology, has been working as urologist for 40 years, out of which 20 years as Head of the Department of Urology, Skåne University Hospital (Malmö/Lund, Trelleborg and Landskrona), Adjunct Secretary General at the European Association of Urology (EAU) 2004-2007 responsible for Science, EAU Secretary General 2007 – 2015, Vice President Global Medical Affairs Uro-oncology, Ferring Pharmaceuticals A/S and Member of the Board at Camurus AB.

IDL Biotech support CancerRehabFonden.

One  in three people in Sweden will develop cancer in their life time. Rehabilitation can help cancer patients to recover, both mentally and physically.  CancerRehabFonden is an Swedish independent organization that provides cancer rehabilitation free of charge.

Positive results for TPS®

Results from a Czech Republic study.

Claes Henning New Scientific Advisor

IDL Biotech continues to strengthen its scientific knowledge by appointing an additional experienced scientific advisor.

Positive results for UBC® Rapid in an Austrian study

International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test.

UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours

Results from a published multicenter study

Hans Örström new Chariman of the Board

The annual general meeting, held 23rd of May 2017, approved the re-election of Jerker Swanstein, Max Pihlqvist, Hans Örström and Peter Brätuigam. During the statutory meeting held 24th of May 2017 Hans Örström was selected as new Chariman of the Board.

Positive results for UBC® Rapid in a Swedish multicenter study

The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was Assoc. Prof Amir Sherif, Umeå University.

Charlotte Berg new CEO

New interesting findings for the tumor marker UBC® Rapid

Result from a new German multicenter study

TUBEX® is getting wider recognition and awareness – Now on social Media.

TUBEX® is getting wider recognition and awareness – Now on social Media.

MonoTotal ELISA has been CE marked in accordance with the European IVD Directive

IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU.

Positive results for UBC Rapid in Clinical study

Evaluation of bladder cancer with point-of-care (POC) tests depends on the detection of bladder cancer associated proteins in urine samples.